Figure 554A contains the amino acid sequence of *H. pylori* polypeptide HPP554 (554A) (SEQ ID NO:937);

Figures 555A and 383B contain the amino acid sequence of *H. pylori* polypeptide HPP555 (555A) (SEQ ID NO:938) and the nucleic acid sequence HPP555B (383B) (SEQ ID NO:383) which encodes HPP555;

Figure 556A contains the amino acid sequence of *H. pylori* polypeptide HPP556 (556A) (SEQ ID NO:939);

Figure 557A contains the amino acid sequence of *H. pylori* polypeptide HPP557 (557A) (SEQ ID NO:940); and

Figure 558A contains the amino acid sequence of *H. pylori* polypeptide HPP558 (558A) (SEQ IS NO:941)--.

In the claims:

Please amend claims 202, 203, 212, 220, 221, 222, 223, and 224 as follows:

2

- 202. (Amended) An isolated polypeptide comprising at least 10 consecutive amino acid residues of SEQ ID NO:809, wherein said polypeptide comprises at least one epitope recognized by a T cell receptor specific for the polypeptide set forth in SEQ ID NO:809.
- 203. (Amended) An isolated polypeptide comprising at least 10 consecutive amino acid residues of SEQ ID NO:809, wherein said polypeptide comprises at least one antigenic determinant of the polypeptide set forth in SEQ ID NO:809.

3

- 212. (Amended) A composition comprising a fusion protein of claim 132 and a pharmaceutically acceptable carrier.
- 220. (Amended) An isolated polypeptide of any one of claims 202-203 comprising at least about 12 consecutive amino acid residues of SEQ ID NO: 809.
- 221. (Amended) An isolated polypeptide of any one of claims 202-203 comprising at least about 16 consecutive amino acid residues of SEQ ID NO: 809.

SEST AVAILABLE COPY


An isolated polypeptide of any one of claims 202-203 comprising 222. (Amended) at least about 20 consecutive amino acid residues of SEQ ID NO: 809.

- An isolated polypeptide of any one of claims 202-203 comprising 223. (Amended) at least about 50 consecutive amino acid residues of SEQ ID NO: 809.
- 224. (Amended) An isolated polypeptide of any one of claims 202-203 comprising at least about 100 consecutive amino acid residues of SEQ ID NO: 809.

Please add new claims 225-235 as follows:

- 225. (New) An isolated polypeptide consisting of at least 10 consecutive amino acid residues of SEQ ID NO: 809, wherein said polypeptide comprises at least one epitope recognized by a T cell receptor specific for the polypeptide set forth in SEQ ID NO:809.
- An isolated polypeptide consisting of at least 10 consecutive amino acid 226. (New) residues of SEQ ID NO: 809, wherein said polypeptide comprises at least one antigenic determinant of the polypeptide set forth in SEQ ID NO: 809.
- An isolated polypeptide of any one of claims 225-226 which is a 227. (New) recombinant polypeptide.
- 228. (New) A fusion protein comprising a polypeptide of any one of claims 225-226 and an additional amino acid sequence.
- A fusion protein of claim 228, wherein the additional amino acid sequence 229. (New) comprises an H. pylori polypeptide.





- A composition comprising a fusion protein of claim 228 and a 231. (New) pharmaceutically acceptable carrier.
- 232. (New) An isolated polypeptide comprising at least 10 consecutive amino acid residues of SEQ ID NO: 809 and no more than 148 amino acid residues of SEQ ID NO:809, wherein said polypeptide comprises at least one epitope recognized by a T cell receptor specific for the polypeptide set forth in SEQ ID NO:809.
- An isolated polypeptide comprising at least 10 consecutive amino acid residues of SEQ ID NO: 809 and no more than 148 amino acid residues of SEQ ID NO:809, wherein said polypeptide comprises at least one antigenic determinant of the polypeptide set forth in SEO ID NO: 809.
- An isolated polypeptide comprising at least 10 consecutive amino acid residues of SEQ ID NO:809, which encodes an antigenic determinant.
- An isolated polypeptide comprising at least 10 consecutive amino acid 235. (New) residues of SEQ ID NO:809, which encodes an epitope.

